What is P3 Health Partners' operating income?

P3 Health Partners' total operating income in 2024 was -$320.66 million, based on the following breakdown: Total Gross Profit: $1.50 billion Total Operating Expenses: $1.82 billion

P3 Health Partners (PIIIW) Financials

$0.01 +0.00 (+13.93%)

As of 01:07 PM Eastern

Compare

Annual Income Statements for P3 Health Partners

This table shows P3 Health Partners' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-42	-31	-270	-58	-136
Consolidated Net Income / (Loss)	-42	-31	-1,562	-186	-310
Net Income / (Loss) Continuing Operations	-42	-31	-1,562	-186	-310
Total Pre-Tax Income	-42	-31	-1,560	-184	-306
Total Operating Income	-40	-29	-1,561	-168	-321
Total Gross Profit	145	491	1,049	1,266	1,500
Total Revenue	145	491	1,049	1,266	1,500
Operating Revenue	145	491	1,049	1,266	1,500
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	185	520	2,610	1,434	1,821
Selling, General & Admin Expense	36	53	157	122	113
Marketing Expense	0.80	1.50	5.10	3.23	1.33
Depreciation Expense	0.40	0.80	87	87	86
Other Operating Expenses / (Income)	147	464	1,046	1,222	1,613
Other Special Charges / (Income)	-	-	-	-	8.06
Total Other Income / (Expense), net	-2.44	-2.82	1.22	-16	15
Interest Expense	2.53	2.53	11	16	22
Other Income / (Expense), net	0.10	-0.29	13	0.18	37
Income Tax Expense	0.00	0.00	1.86	2.70	4.39
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	0.00	-1,291	-129	-175
Basic Earnings per Share	$0.00	$0.00	($6.50)	($0.61)	($46.78)
Weighted Average Basic Shares Outstanding	-	-	41.58M	94.89M	2.90M
Diluted Earnings per Share	$0.00	$0.00	($6.50)	($0.63)	($54.06)
Weighted Average Diluted Shares Outstanding	-	-	41.58M	294.59M	2.94M
Weighted Average Basic & Diluted Shares Outstanding	-	-	41.58K	315.90M	7.21M

This table shows P3 Health Partners' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-13	-25	-19	-12	-47	-59	-20	-20	-32	1.22
Consolidated Net Income / (Loss)	-37	-69	-50	-29	-103	-129	-44	-44	-69	3.04
Net Income / (Loss) Continuing Operations	-37	-69	-50	-29	-103	-129	-44	-44	-69	3.04
Total Pre-Tax Income	-37	-67	-48	-28	-106	-124	-43	-42	-69	-7.96
Total Operating Income	-34	-64	-44	-31	-107	-139	-38	-34	-44	8.24
Total Gross Profit	288	347	388	379	362	371	373	356	345	386
Total Revenue	288	347	388	379	362	371	373	356	345	386
Operating Revenue	288	347	388	379	362	371	373	356	345	386
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00
Total Operating Expenses	322	411	432	410	469	509	411	390	389	378
Selling, General & Admin Expense	33	24	27	27	27	31	25	23	22	26
Marketing Expense	0.65	0.72	0.32	0.41	0.13	0.46	0.18	0.15	0.25	0.23
Depreciation Expense	22	22	22	22	22	21	21	21	21	21
Other Operating Expenses / (Income)	267	364	383	362	420	448	365	345	346	331
Total Other Income / (Expense), net	-3.06	-3.08	-3.70	3.53	0.54	14	-5.09	-7.56	-25	-16
Interest Expense	4.00	4.05	4.26	5.44	5.65	6.83	8.73	10	21	17
Other Income / (Expense), net	0.95	0.97	0.55	8.96	6.18	21	3.64	2.59	-4.70	0.57
Income Tax Expense	0.41	1.77	2.07	0.97	-3.61	4.95	1.07	1.98	0.01	-11
Net Income / (Loss) Attributable to Noncontrolling Interest	-24	-44	-31	-17	-56	-71	-24	-23	-38	1.82
Basic Earnings per Share	($0.12)	($0.18)	($7.86)	($4.40)	($14.36)	($0.40)	($6.28)	($6.23)	($9.67)	$0.37
Weighted Average Basic Shares Outstanding	114.20M	94.89M	2.38M	2.73M	3.24M	145.18M	3.26M	3.27M	3.27M	3.29M
Diluted Earnings per Share	($0.12)	($0.20)	($7.86)	($7.37)	($15.70)	($0.46)	($6.28)	($6.23)	($9.67)	$0.32
Weighted Average Diluted Shares Outstanding	312.68M	294.59M	2.38M	2.82M	3.29M	147.00M	3.26M	3.27M	3.27M	8.42M
Weighted Average Basic & Diluted Shares Outstanding	313.09M	315.90M	316.11M	357.72M	358.82M	359.12M	7.19M	7.19M	7.21M	7.24M

This table details how cash moves in and out of P3 Health Partners' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	31	7.00	-122	22	-11
Net Cash From Operating Activities	-28	-25	-126	-76	-110
Net Cash From Continuing Operating Activities	-28	-25	-126	-76	-110
Net Income / (Loss) Continuing Operations	-42	-31	-1,562	-186	-310
Consolidated Net Income / (Loss)	-42	-31	-1,562	-186	-310
Depreciation Expense	0.40	0.80	87	87	86
Amortization Expense	0.00	0.23	0.00	0.47	0.09
Non-Cash Adjustments To Reconcile Net Income	11	-1.72	1,330	-28	129
Changes in Operating Assets and Liabilities, net	2.19	7.52	18	51	-15
Net Cash From Investing Activities	-3.86	-3.17	-7.73	-1.83	15
Net Cash From Continuing Investing Activities	-3.86	-3.17	-7.73	-1.83	0.00
Purchase of Property, Plant & Equipment	-1.45	-2.93	-2.23	-1.83	0.00
Sale of Property, Plant & Equipment	-	-	-	0.00	0.00
Net Cash From Financing Activities	64	35	11	100	99
Net Cash From Continuing Financing Activities	64	35	11	100	99
Repayment of Debt	-15	-1.49	-3.63	-0.17	-31
Issuance of Debt	78	36	15	14	90
Issuance of Common Equity	-	-	0.00	87	40
Other Financing Activities, net	0.00	0.00	0.00	-0.19	-0.58
Cash Interest Paid	0.56	0.69	5.71	5.81	14
Cash Income Taxes Paid	-	-	0.00	0.57	5.48

This table details how cash moves in and out of P3 Health Partners' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Net Change in Cash & Equivalents	-8.06	-17	-8.63	46	-10	-24	-2.81	-1.97	-0.87	0.30
Net Cash From Operating Activities	-7.59	-16	-20	-10	-23	-57	-33	-17	-15	-27
Net Cash From Continuing Operating Activities	-7.59	-16	-20	-10	-23	-57	-33	-17	-15	-27
Net Income / (Loss) Continuing Operations	-37	-69	-50	-29	-103	-129	-44	-44	-69	3.04
Consolidated Net Income / (Loss)	-37	-69	-50	-29	-103	-129	-44	-44	-69	3.04
Depreciation Expense	22	22	22	22	22	21	21	21	21	21
Amortization Expense	0.07	0.07	-0.14	0.05	0.10	0.07	0.33	0.07	11	2.80
Non-Cash Adjustments To Reconcile Net Income	6.60	-8.77	-33	34	14	65	2.21	12	27	-53
Changes in Operating Assets and Liabilities, net	1.32	40	41	-37	44	-15	-13	-6.50	-5.02	-1.49
Net Cash From Investing Activities	-0.39	0.21	0.00	-	15	-0.48	0.00	0.05	-0.12	-0.04
Net Cash From Continuing Investing Activities	-0.39	0.21	0.00	-	15	-0.48	0.00	0.05	-0.12	-0.04
Other Investing Activities, net	-	-	-	-	-	-	0.00	-	-	-0.04
Net Cash From Financing Activities	-0.09	-0.84	11	56	-2.49	34	31	15	15	28
Net Cash From Continuing Financing Activities	-0.09	-0.84	11	56	-2.49	34	31	15	15	28
Repayment of Debt	-	-	-0.43	-0.61	-0.72	-29	-0.48	-0.38	-0.33	-0.24
Issuance of Debt	-0.00	-	12	15	-	63	31	15	15	28

This table presents P3 Health Partners' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2025	12/31/2025
Total Assets	106	2,364	877	861	657	657
Total Current Assets	91	200	101	166	133	133
Cash & Equivalents	36	140	18	36	25	25
Restricted Cash	3.64	0.36	0.92	4.61	0.80	0.80
Note & Lease Receivable	-	-	72	118	92	92
Prepaid Expenses	5.19	6.96	2.64	3.61	11	11
Other Current Assets	46	51	7.50	2.97	3.38	3.38
Plant, Property, & Equipment, net	6.15	8.05	8.84	8.69	3.37	3.37
Total Noncurrent Assets	9.40	2,156	767	686	520	520
Intangible Assets	0.00	836	751	667	492	492
Other Noncurrent Operating Assets	4.73	11	16	20	28	28
Total Liabilities & Shareholders' Equity	106	2,364	877	861	657	657
Total Liabilities	146	300	354	427	797	797
Total Current Liabilities	91	199	242	299	545	545
Short-Term Debt	0.09	3.63	-	0.00	45	45
Accounts Payable	12	5.47	12	8.66	12	12
Accrued Expenses	4.00	19	17	37	42	43
Current Employee Benefit Liabilities	-	-	8.22	3.51	1.95	1.95
Other Current Liabilities	71	162	191	227	444	444
Total Noncurrent Liabilities	55	101	112	128	252	252
Long-Term Debt	45	80	94	108	228	228
Other Noncurrent Operating Liabilities	9.95	21	18	20	23	23
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	181	1,791	517	292	15	15
Total Equity & Noncontrolling Interests	-130	274	5.85	142	-155	-155
Total Preferred & Common Equity	-130	274	5.85	142	-155	-155
Total Common Equity	-130	274	5.85	142	-155	-155
Common Stock	0.00	313	315	509	496	496
Retained Earnings	-130	-39	-310	-367	-651	-651
Noncontrolling Interest	-	-	-	-	-	0.00

This table presents P3 Health Partners' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	897	856	893	833	784	732	684	674
Total Current Assets	180	183	242	215	191	157	136	172
Cash & Equivalents	53	27	73	63	40	39	38	25
Restricted Cash	4.88	5.01	5.12	5.14	1.21	0.75	0.75	0.61
Note & Lease Receivable	117	144	153	123	129	93	82	125
Prepaid Expenses	2.80	6.91	8.48	11	15	16	11	12
Other Current Assets	2.23	0.05	2.17	2.50	5.41	7.57	3.74	9.06
Plant, Property, & Equipment, net	9.36	8.12	7.54	6.32	5.31	4.69	3.90	2.96
Total Noncurrent Assets	708	665	643	612	587	570	544	499
Intangible Assets	688	646	625	595	554	533	513	473
Other Noncurrent Operating Assets	20	19	18	17	33	37	31	26
Total Liabilities & Shareholders' Equity	897	856	893	833	784	732	684	674
Total Liabilities	396	470	528	569	663	644	665	807
Total Current Liabilities	267	334	352	405	507	505	424	525
Short-Term Debt	-	1.44	0.83	0.21	66	80	39	52
Accounts Payable	12	12	7.99	13	12	14	9.93	12
Accrued Expenses	21	29	40	49	28	30	36	43
Current Employee Benefit Liabilities	5.63	5.05	3.74	4.41	3.22	1.16	1.35	2.77
Other Current Liabilities	208	259	268	301	386	352	338	416
Total Noncurrent Liabilities	129	137	176	164	156	139	241	282
Long-Term Debt	108	118	133	133	106	102	214	260
Other Noncurrent Operating Liabilities	20	19	43	31	50	37	26	22
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	313	239	198	143	58	43	38	10
Total Equity & Noncontrolling Interests	188	147	167	121	63	44	-19	-144
Total Preferred & Common Equity	188	147	167	121	63	44	-19	-145
Total Common Equity	188	147	167	121	63	44	-19	-145
Common Stock	530	533	565	565	587	588	557	505
Retained Earnings	-342	-386	-398	-445	-524	-544	-576	-650
Noncontrolling Interest	-	-	-	-	-	-	-	1.36

This table displays calculated financial ratios and metrics derived from P3 Health Partners' official financial filings.

Metric	2019	2020	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	237.54%	0.00%	20.67%	18.48%
EBITDA Growth	0.00%	28.64%	0.00%	94.48%	-145.25%
EBIT Growth	0.00%	26.77%	0.00%	89.17%	-69.20%
NOPAT Growth	0.00%	27.69%	0.00%	89.24%	-90.95%
Net Income Growth	0.00%	25.16%	0.00%	88.06%	-66.49%
EPS Growth	0.00%	0.00%	0.00%	90.31%	-71.43%
Operating Cash Flow Growth	0.00%	13.05%	0.00%	39.67%	-44.85%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%	193.27%
Invested Capital Growth	0.00%	0.00%	0.00%	-14.36%	-48.03%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	7.53%	1.61%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	85.20%	-38.11%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	73.46%	-23.53%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	73.77%	-30.13%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	71.30%	-23.98%
EPS Q/Q Growth	0.00%	0.00%	0.00%	76.49%	-31.71%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	17.45%	-60.14%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-133.48%	-38.31%
Invested Capital Q/Q Growth	0.00%	0.00%	-44.78%	-8.43%	-23.37%
Profitability Metrics	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-26.83%	-5.67%	-139.21%	-6.36%	-13.17%
Operating Margin	-27.18%	-5.82%	-148.73%	-13.26%	-21.37%
EBIT Margin	-27.11%	-5.88%	-147.53%	-13.25%	-18.92%
Profit (Net Income) Margin	-28.85%	-6.40%	-148.79%	-14.72%	-20.69%
Tax Burden Percent	100.00%	100.00%	100.12%	101.47%	101.43%
Interest Burden Percent	106.42%	108.77%	100.74%	109.53%	107.81%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-178.34%	-20.67%	-56.30%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-699.21%	-96.75%	-136.54%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	-120.44%	-18.32%	-50.14%
Return on Equity (ROE)	0.00%	-61.38%	-298.77%	-38.99%	-106.44%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-5.20%	6.92%
Operating Return on Assets (OROA)	0.00%	-27.13%	-95.55%	-19.31%	-34.52%
Return on Assets (ROA)	0.00%	-29.51%	-96.37%	-21.46%	-37.75%
Return on Common Equity (ROCE)	0.00%	155.95%	-32.27%	-6.03%	-39.80%
Return on Equity Simple (ROE_SIMPLE)	0.00%	24.16%	0.00%	-131.17%	-408.74%
Net Operating Profit after Tax (NOPAT)	-28	-20	-1,093	-118	-224
NOPAT Margin	-19.02%	-4.08%	-104.11%	-9.28%	-14.96%
Net Nonoperating Expense Percent (NNEP)	0.00%	-28.12%	520.88%	76.08%	80.23%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-46.94%	-97.27%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	25.04%	10.87%	14.99%	9.66%	7.50%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	127.18%	105.82%	248.73%	113.26%	121.37%
Earnings before Interest and Taxes (EBIT)	-39	-29	-1,548	-168	-284
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-39	-28	-1,461	-81	-198
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	76.57	3.11	1.06
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.89	0.56	0.43	0.35	0.05
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	1.70	1.53	0.97
Enterprise Value to Revenue (EV/Rev)	0.00	0.94	0.99	0.63	0.18
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	46.75	0.00	0.00	9.61
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.89	0.18	0.25	1.04
Long-Term Debt to Equity	0.00	0.89	0.18	0.25	0.60
Financial Leverage	0.00	-1.58	0.17	0.19	0.37
Leverage Ratio	0.00	2.08	1.25	1.82	2.82
Compound Leverage Factor	0.00	2.26	1.26	1.99	3.04
Debt to Total Capital	0.00%	47.05%	15.30%	19.99%	50.87%
Short-Term Debt to Total Capital	0.00%	0.09%	0.00%	0.00%	21.36%
Long-Term Debt to Total Capital	0.00%	46.96%	15.30%	19.99%	29.51%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	187.67%	83.75%	53.79%	24.18%
Common Equity to Total Capital	0.00%	-134.54%	0.95%	26.22%	24.95%
Debt to EBITDA	0.00	-1.63	-0.06	-1.34	-0.78
Net Debt to EBITDA	0.00	-0.20	-0.05	-0.84	-0.56
Long-Term Debt to EBITDA	0.00	-1.63	-0.06	-1.34	-0.45
Debt to NOPAT	0.00	-2.27	-0.09	-0.92	-0.69
Net Debt to NOPAT	0.00	-0.28	-0.07	-0.57	-0.49
Long-Term Debt to NOPAT	0.00	-2.27	-0.09	-0.92	-0.40
Altman Z-Score	0.00	3.14	-4.56	0.66	-0.58
Noncontrolling Interest Sharing Ratio	0.00%	354.09%	89.20%	84.53%	62.61%
Liquidity Ratios	-	-	-	-	-
Current Ratio	0.00	1.00	0.42	0.55	0.37
Quick Ratio	0.00	0.40	0.37	0.52	0.32
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	9.88	0.00	-30	28
Operating Cash Flow to CapEx	-1,948.29%	-840.42%	-5,643.48%	-4,161.36%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	3.90	0.00	-1.85	1.24
Operating Cash Flow to Interest Expense	-11.16	-9.71	-11.05	-4.76	-4.97
Operating Cash Flow Less CapEx to Interest Expense	-11.74	-10.86	-11.25	-4.87	-4.31
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	4.61	0.65	1.46	1.82
Accounts Receivable Turnover	0.00	3,360.76	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	79.84	124.29	144.52	208.11
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.11	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.11	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	0.00	-30	613	525	273
Invested Capital Turnover	0.00	-32.86	1.71	2.23	3.76
Increase / (Decrease) in Invested Capital	0.00	-30	0.00	-88	-252
Enterprise Value (EV)	0.00	462	1,041	800	265
Market Capitalization	275	275	448	441	81
Book Value per Share	$0.00	($4.73)	$0.02	$0.45	$0.21
Tangible Book Value per Share	$0.00	($4.76)	($3.06)	($1.68)	($1.39)
Total Capital	0.00	97	617	542	304
Total Debt	0.00	45	94	108	155
Total Long-Term Debt	0.00	45	94	108	90
Net Debt	0.00	5.58	76	67	111
Capital Expenditures (CapEx)	1.45	2.93	2.23	1.83	-15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-40	-159	-174	-291
Debt-free Net Working Capital (DFNWC)	0.00	0.35	-141	-133	-247
Net Working Capital (NWC)	0.00	0.26	-141	-133	-312
Net Nonoperating Expense (NNE)	14	11	469	69	86
Net Nonoperating Obligations (NNO)	0.00	-81	90	91	123
Total Depreciation and Amortization (D&A)	0.40	1.02	87	87	86
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-8.05%	-15.19%	-13.76%	-19.42%
Debt-free Net Working Capital to Revenue	0.00%	0.07%	-13.43%	-10.53%	-16.48%
Net Working Capital to Revenue	0.00%	0.05%	-13.43%	-10.53%	-20.81%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($6.50)	($0.61)	($0.94)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	41.58K	94.89M	145.18M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($6.50)	($0.63)	($1.08)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	41.58K	294.59M	147.00M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	41.58K	315.90M	359.12M
Normalized Net Operating Profit after Tax (NOPAT)	-28	-20	-172	-118	-219
Normalized NOPAT Margin	-19.02%	-4.08%	-16.41%	-9.28%	-14.58%
Pre Tax Income Margin	-28.85%	-6.40%	-148.62%	-14.51%	-20.39%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	-15.56	-11.40	-135.77	-10.49	-12.80
NOPAT to Interest Expense	-10.92	-7.90	-95.81	-7.35	-10.12
EBIT Less CapEx to Interest Expense	-16.14	-12.56	-135.96	-10.61	-12.15
NOPAT Less CapEx to Interest Expense	-11.50	-9.06	-96.01	-7.47	-9.47
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from P3 Health Partners' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
DEI Shares Outstanding	312,676,611.00	313,088,799.00	315,903,414.00	316,114,705.00	357,719,042.00	-	359,116,532.00	7,188,017.00	7,187,342.00	7,213,414.00
DEI Adjusted Shares Outstanding	6,253,532.00	6,261,776.00	6,318,068.00	6,322,294.00	7,154,381.00	-	7,182,331.00	7,188,017.00	7,187,342.00	7,213,414.00
DEI Earnings Per Adjusted Shares Outstanding	-2.13	-4.07	-2.96	-1.90	-6.50	-	-2.85	-2.83	-4.39	0.17
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	16.15%	34.33%	28.61%	15.22%	25.58%	6.87%	-3.93%	-6.16%	-4.66%	3.53%
EBITDA Growth	72.65%	91.77%	16.66%	62.26%	-612.70%	-131.13%	40.29%	-1,553.66%	78.60%	350.18%
EBIT Growth	47.29%	88.00%	9.97%	4.83%	-206.64%	-85.42%	20.40%	-40.99%	51.47%	125.57%
NOPAT Growth	43.64%	88.02%	10.21%	-48.98%	-216.35%	-115.54%	13.10%	-8.90%	58.67%	121.63%
Net Income Growth	42.92%	87.02%	5.42%	-4.32%	-175.82%	-86.88%	10.81%	-51.75%	32.46%	106.87%
EPS Growth	55.56%	91.11%	5.42%	-4.32%	-175.82%	-130.00%	10.81%	15.47%	38.41%	105.10%
Operating Cash Flow Growth	63.84%	50.31%	15.56%	64.49%	-198.15%	-260.49%	-67.08%	-62.40%	31.86%	17.93%
Free Cash Flow Firm Growth	160.65%	0.00%	108.97%	-78.03%	-72.25%	260.60%	276.89%	45.23%	-35.90%	-44.16%
Invested Capital Growth	-48.35%	-14.36%	-14.72%	-23.62%	-37.90%	-48.03%	-47.26%	-43.16%	-34.33%	-42.22%
Revenue Q/Q Growth	-12.38%	20.29%	12.00%	-2.40%	-4.49%	2.36%	13.34%	-4.67%	-2.96%	0.00%
EBITDA Q/Q Growth	-566.41%	-275.08%	47.40%	97.13%	-12,484.55%	-21.64%	80.39%	20.51%	-62.82%	0.00%
EBIT Q/Q Growth	-39.86%	-92.53%	31.62%	48.31%	-350.64%	-16.42%	65.35%	8.44%	-55.12%	0.00%
NOPAT Q/Q Growth	-60.79%	-90.01%	31.79%	28.51%	-241.45%	-29.45%	56.79%	10.41%	-29.60%	0.00%
Net Income Q/Q Growth	-35.19%	-85.33%	28.22%	41.99%	-257.44%	-25.57%	68.81%	1.31%	-59.08%	0.00%
EPS Q/Q Growth	-33.33%	-66.67%	28.22%	41.99%	-257.44%	-48.39%	68.81%	0.80%	-55.22%	0.00%
Operating Cash Flow Q/Q Growth	73.70%	-109.31%	-26.15%	48.87%	-120.84%	-153.06%	12.73%	50.30%	7.34%	0.00%
Free Cash Flow Firm Q/Q Growth	-4.54%	-91.61%	29.56%	111.82%	20.56%	8.99%	-40.88%	-18.38%	-46.79%	0.00%
Invested Capital Q/Q Growth	-3.28%	-8.43%	-4.57%	-9.63%	-21.37%	-23.37%	144.96%	-2.60%	-9.15%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-3.85%	-11.99%	-5.63%	-0.17%	-21.82%	-25.93%	-3.50%	-2.92%	-4.90%	8.46%
Operating Margin	-11.73%	-18.53%	-11.28%	-8.26%	-29.55%	-37.36%	-10.21%	-9.59%	-12.81%	2.13%
EBIT Margin	-11.40%	-18.25%	-11.14%	-5.90%	-27.84%	-31.66%	-9.23%	-8.86%	-14.17%	2.28%
Profit (Net Income) Margin	-12.93%	-19.92%	-12.77%	-7.59%	-28.40%	-34.84%	-11.86%	-12.27%	-20.12%	0.79%
Tax Burden Percent	101.12%	102.62%	104.36%	103.48%	96.61%	103.99%	102.49%	104.75%	100.02%	-38.21%
Interest Burden Percent	112.17%	106.39%	109.83%	124.30%	105.60%	105.82%	125.33%	132.17%	141.96%	-90.33%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-11.49%	-28.88%	-19.64%	-15.53%	-65.76%	-98.44%	-26.97%	-27.66%	-43.96%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-32.56%	-55.53%	-36.00%	-24.71%	-99.88%	-128.50%	-40.59%	-43.01%	-69.07%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-2.71%	-10.51%	-9.73%	-4.11%	-21.40%	-47.19%	-20.70%	-24.52%	-74.88%	0.00%
Return on Equity (ROE)	-14.20%	-39.39%	-29.37%	-19.64%	-87.16%	-145.63%	-47.67%	-52.18%	-118.84%	0.00%
Cash Return on Invested Capital (CROIC)	10.50%	-5.20%	-5.09%	3.58%	9.62%	6.92%	13.46%	-7.64%	-19.10%	53.52%
Operating Return on Assets (OROA)	-11.78%	-26.60%	-17.49%	-9.19%	-47.52%	-57.78%	-16.25%	-15.96%	-27.00%	0.00%
Return on Assets (ROA)	-13.36%	-29.04%	-20.05%	-11.82%	-48.48%	-63.58%	-20.88%	-22.09%	-38.33%	0.00%
Return on Common Equity (ROCE)	-2.43%	-6.10%	-4.93%	-0.67%	-35.15%	-54.45%	-19.75%	-24.39%	-42.78%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-345.66%	0.00%	-125.23%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-24	-45	-31	-22	-75	-97	-27	-24	-31	5.77
NOPAT Margin	-8.21%	-12.97%	-7.90%	-5.78%	-20.68%	-26.15%	-7.14%	-6.71%	-8.97%	1.49%
Net Nonoperating Expense Percent (NNEP)	21.07%	26.65%	16.36%	9.18%	34.12%	30.07%	13.62%	15.35%	25.12%	1.27%
Return On Investment Capital (ROIC_SIMPLE)	-	-17.96%	-11.53%	-7.29%	-29.49%	-42.01%	-11.34%	-10.53%	-13.22%	3.43%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	11.47%	7.04%	7.05%	7.02%	7.52%	8.46%	6.70%	6.55%	6.41%	6.61%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	111.73%	118.53%	111.28%	108.26%	129.55%	137.36%	110.21%	109.59%	112.81%	97.87%
Earnings before Interest and Taxes (EBIT)	-33	-63	-43	-22	-101	-117	-34	-32	-49	8.81
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-11	-42	-22	-0.63	-79	-96	-13	-10	-17	33
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.45	3.11	2.22	0.85	1.15	1.06	0.93	1.02	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.39	0.35	0.24	0.10	0.09	0.05	0.04	0.03	0.04	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.44	1.53	1.30	0.88	0.98	0.97	0.94	0.90	1.35	2.10
Enterprise Value to Revenue (EV/Rev)	0.70	0.63	0.48	0.28	0.23	0.18	0.17	0.16	0.22	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	9.33	0.00	0.00	21.20	7.76	9.61	4.81	0.00	0.00	2.87
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.22	0.25	0.31	0.37	0.51	1.04	1.42	2.09	13.36	-2.34
Long-Term Debt to Equity	0.22	0.25	0.31	0.36	0.50	0.60	0.88	1.17	11.32	-1.95
Financial Leverage	0.08	0.19	0.27	0.17	0.21	0.37	0.51	0.57	1.08	-35.47
Leverage Ratio	1.47	1.82	2.01	2.01	2.26	2.82	3.24	3.59	5.36	-120.62
Compound Leverage Factor	1.65	1.93	2.21	2.50	2.39	2.98	4.06	4.75	7.61	108.95
Debt to Total Capital	17.77%	19.99%	23.68%	26.86%	33.58%	50.87%	58.68%	67.66%	93.04%	174.53%
Short-Term Debt to Total Capital	0.00%	0.00%	0.29%	0.17%	0.05%	21.36%	22.46%	29.84%	14.25%	29.26%
Long-Term Debt to Total Capital	17.77%	19.99%	23.39%	26.69%	33.53%	29.51%	36.22%	37.82%	78.79%	145.28%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	51.39%	53.79%	47.29%	39.69%	36.09%	24.18%	19.74%	15.85%	13.84%	6.57%
Common Equity to Total Capital	30.85%	26.22%	29.03%	33.45%	30.33%	24.95%	21.59%	16.49%	-6.87%	-81.10%
Debt to EBITDA	-0.20	-1.34	-1.57	-1.78	-0.93	-0.78	-1.08	-0.92	-1.85	0.00
Net Debt to EBITDA	-0.09	-0.84	-1.14	-0.74	-0.46	-0.56	-0.82	-0.72	-1.57	0.00
Long-Term Debt to EBITDA	-0.20	-1.34	-1.55	-1.77	-0.93	-0.45	-0.67	-0.51	-1.57	0.00
Debt to NOPAT	-0.24	-0.92	-1.05	-1.10	-0.77	-0.69	-0.93	-0.82	-1.42	0.00
Net Debt to NOPAT	-0.11	-0.57	-0.77	-0.46	-0.38	-0.49	-0.71	-0.64	-1.20	0.00
Long-Term Debt to NOPAT	-0.24	-0.92	-1.04	-1.10	-0.77	-0.40	-0.57	-0.46	-1.20	0.00
Altman Z-Score	1.24	1.06	0.99	0.88	0.50	0.12	0.33	0.29	0.25	-1.92
Noncontrolling Interest Sharing Ratio	82.87%	84.53%	83.20%	96.58%	59.68%	62.61%	58.57%	53.25%	64.00%	-575.53%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.67	0.55	0.55	0.69	0.53	0.37	0.38	0.31	0.32	0.33
Quick Ratio	0.64	0.52	0.51	0.64	0.46	0.32	0.33	0.26	0.28	0.29
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	513	43	56	118	142	155	210	171	91	117
Operating Cash Flow to CapEx	-1,960.21%	0.00%	0.00%	0.00%	0.00%	-12,050.11%	0.00%	0.00%	-12,951.26%	0.00%
Free Cash Flow to Firm to Interest Expense	128.13	10.63	13.09	21.71	25.20	22.69	24.07	16.90	4.44	6.99
Operating Cash Flow to Interest Expense	-1.90	-3.92	-4.71	-1.88	-4.01	-8.38	-3.84	-1.64	-0.75	-1.64
Operating Cash Flow Less CapEx to Interest Expense	-1.99	-3.87	-4.71	-1.88	-1.35	-8.45	-3.84	-1.63	-0.76	-1.64
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.03	1.46	1.57	1.56	1.71	1.82	1.76	1.80	1.91	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	124.79	144.52	158.52	164.48	188.41	208.11	215.03	239.17	282.85	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	573	525	501	452	356	273	264	257	234	153
Invested Capital Turnover	1.40	2.23	2.49	2.69	3.18	3.76	3.78	4.12	4.90	0.00
Increase / (Decrease) in Invested Capital	-536	-88	-86	-140	-217	-252	-237	-195	-122	-111
Enterprise Value (EV)	824	800	651	396	347	265	247	231	316	320
Market Capitalization	460	441	325	142	138	81	59	45	64	22
Book Value per Share	$0.60	$0.45	$0.46	$0.53	$0.34	$0.21	$0.18	$6.19	($2.60)	($20.09)
Tangible Book Value per Share	($1.60)	($1.68)	($1.58)	($1.45)	($1.33)	($1.39)	($1.37)	($68.02)	($73.96)	($85.66)
Total Capital	609	542	505	499	397	304	293	270	272	179
Total Debt	108	108	120	134	133	155	172	182	253	312
Total Long-Term Debt	108	108	118	133	133	90	106	102	214	260
Net Debt	51	67	87	56	65	111	131	143	214	286
Capital Expenditures (CapEx)	0.39	-0.21	0.00	0.00	-15	0.48	0.00	-0.05	0.12	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-145	-174	-182	-188	-258	-291	-291	-307	-288	-327
Debt-free Net Working Capital (DFNWC)	-88	-133	-149	-109	-190	-247	-250	-268	-250	-301
Net Working Capital (NWC)	-88	-133	-151	-110	-190	-312	-316	-348	-288	-353
Net Nonoperating Expense (NNE)	14	24	19	6.84	28	32	18	20	39	2.73
Net Nonoperating Obligations (NNO)	72	91	115	88	92	123	143	170	215	286
Total Depreciation and Amortization (D&A)	22	22	21	22	22	21	21	21	32	24
Debt-free, Cash-free Net Working Capital to Revenue	-12.32%	-13.76%	-13.42%	-13.37%	-17.48%	-19.42%	-20.16%	-21.02%	-19.94%	0.00%
Debt-free Net Working Capital to Revenue	-7.44%	-10.53%	-11.03%	-7.79%	-12.87%	-16.48%	-17.30%	-18.33%	-17.27%	0.00%
Net Working Capital to Revenue	-7.44%	-10.53%	-11.14%	-7.85%	-12.88%	-20.81%	-21.86%	-23.84%	-19.95%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.12)	($0.18)	($8.00)	($4.50)	($14.50)	($0.40)	($6.28)	($6.23)	($9.67)	$0.37
Adjusted Weighted Average Basic Shares Outstanding	114.20M	94.89M	2.38M	2.73M	3.24M	145.18M	3.26M	3.27M	3.27M	3.29M
Adjusted Diluted Earnings per Share	($0.12)	($0.20)	($8.00)	($7.50)	($15.50)	($0.46)	($6.28)	($6.23)	($9.67)	$0.32
Adjusted Weighted Average Diluted Shares Outstanding	312.68M	294.59M	2.38M	2.82M	3.29M	147.00M	3.26M	3.27M	3.27M	8.42M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	313.09M	315.90M	6.32M	7.15M	7.18M	359.12M	7.19M	7.19M	7.21M	7.24M
Normalized Net Operating Profit after Tax (NOPAT)	-24	-45	-31	-22	-75	-97	-27	-24	-31	5.77
Normalized NOPAT Margin	-8.21%	-12.97%	-7.90%	-5.78%	-20.68%	-26.15%	-7.14%	-6.71%	-8.97%	1.49%
Pre Tax Income Margin	-12.79%	-19.41%	-12.24%	-7.33%	-29.40%	-33.50%	-11.57%	-11.72%	-20.12%	-2.06%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-8.21	-15.64	-10.17	-4.12	-17.85	-17.17	-3.95	-3.11	-2.38	0.53
NOPAT to Interest Expense	-5.92	-11.12	-7.21	-4.03	-13.26	-14.19	-3.06	-2.35	-1.51	0.34
EBIT Less CapEx to Interest Expense	-8.31	-15.59	-10.17	-4.12	-15.20	-17.24	-3.95	-3.10	-2.39	0.53
NOPAT Less CapEx to Interest Expense	-6.01	-11.07	-7.21	-4.03	-10.61	-14.26	-3.06	-2.35	-1.51	0.34
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

P3 Health Partners Financials - Frequently Asked Questions

According to the most recent income statement we have on file, P3 Health Partners' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

P3 Health Partners' net income appears to be on an upward trend, with a most recent value of -$310.38 million in 2024, rising from -$41.97 million in 2019. The previous period was -$186.43 million in 2023.

P3 Health Partners' total operating income in 2024 was -$320.66 million, based on the following breakdown:

Total Gross Profit: $1.50 billion
Total Operating Expenses: $1.82 billion

Over the last 4 years, P3 Health Partners' total revenue changed from $145.48 million in 2019 to $1.50 billion in 2024, a change of 931.4%.

P3 Health Partners' total liabilities were at $796.88 million at the end of 2025, which was unchanged from 2024, and a 446.0% increase since 2020.

In the past 5 years, P3 Health Partners' cash and equivalents has ranged from $17.54 million in 2022 to $140.48 million in 2021, and is currently $25.01 million as of their latest financial filing in 2025.

Over the last 4 years, P3 Health Partners' book value per share changed from 0.00 in 2019 to 0.21 in 2024, a change of 21.2%.

Related Companies

Financial statements for NASDAQ:PIIIW last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

P3 Health Partners (PIIIW) Financials

Financials Breakdown Chart

P3 Health Partners Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

P3 Health Partners (PIIIW) Financials

Annual Income Statements for P3 Health Partners

Quarterly Income Statements for P3 Health Partners

Annual Cash Flow Statements for P3 Health Partners

Quarterly Cash Flow Statements for P3 Health Partners

Annual Balance Sheets for P3 Health Partners

Quarterly Balance Sheets for P3 Health Partners

Annual Metrics And Ratios for P3 Health Partners

Quarterly Metrics And Ratios for P3 Health Partners

Financials Breakdown Chart

P3 Health Partners Financials - Frequently Asked Questions

When does P3 Health Partners' fiscal year end?

How has P3 Health Partners' net income changed over the last 4 years?

What is P3 Health Partners' operating income?

How has P3 Health Partners' revenue changed over the last 4 years?

How much debt does P3 Health Partners have?

How much cash does P3 Health Partners have?

How has P3 Health Partners' book value per share changed over the last 4 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools